Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 26

Results For "president"

1772 News Found

Department of Biotechnology hosts webinar on biomanufacturing of enzymes
Biotech | December 28, 2024

Department of Biotechnology hosts webinar on biomanufacturing of enzymes

The session focused on “Biomanufacturing of Enzymes,” a critical domain under the BioE3 Policy.


Mankind Pharma and Innovent Biologics join forces for cancer care with Sintilimab
News | December 27, 2024

Mankind Pharma and Innovent Biologics join forces for cancer care with Sintilimab

Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India


Thyrocare secures NABL accreditation for its Labs
News | December 27, 2024

Thyrocare secures NABL accreditation for its Labs

Thyrocare becomes first national diagnostic chain with 100% of its labs with NABL accreditation


Sumitomo Pharma America receives USFDA approval of vibegron for benign prostatic hyperplasia
Drug Approval | December 27, 2024

Sumitomo Pharma America receives USFDA approval of vibegron for benign prostatic hyperplasia

GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH


Syensqo and Emulseo collaborate to advance microfluidic technology in healthcare sector
News | December 24, 2024

Syensqo and Emulseo collaborate to advance microfluidic technology in healthcare sector

Exploring new opportunities within the fast-growing market of microfluidics


USFDA approves Encorafenib plus Cetuximab and Chemo in BRAF V600E-positive mCRC
Drug Approval | December 21, 2024

USFDA approves Encorafenib plus Cetuximab and Chemo in BRAF V600E-positive mCRC

Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the


Glenmark USA launches Lacosamide Oral Solution, 10 mg/mL
News | December 17, 2024

Glenmark USA launches Lacosamide Oral Solution, 10 mg/mL

According to IQVIATM sales data for the 12-month period ending October 2024, the Vimpat Oral Solution, 10 mg/mL market achieved annual sales of approximately $57.0 million


Merck to discontinue KeyVibe and Keyform clinical trials
Diagnostic Center | December 17, 2024

Merck to discontinue KeyVibe and Keyform clinical trials

Merck has also decided to end the favezelimab clinical development program